Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07722182 Sponsor: Chinese University of Hong Kong Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07722182
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People with early-stage non-small cell lung cancer (a specific type of lung cancer) that is small (3 cm or less) and has not spread to lymph nodes or other parts of the body, based on standard tests and review by a specialist team.
  • People whose lung cancer has been confirmed by a tissue or cell sample where possible; if getting a sample is not safely possible, a specialist team may still consider someone eligible based on scans and clinical assessment that strongly suggest lung cancer (confirm with trial site).
  • People whose cancer is considered unsuitable for surgery for medical reasons, or who have chosen not to have surgery after discussion with a specialist team, and for whom both treatment options in this trial — bronchoscopy-guided microwave ablation and a type of targeted radiation therapy called SBRT — are both considered appropriate by the treating doctors.
  • People whose lung tumour is technically suitable and safe to treat with both of the treatment methods being compared in this trial.
  • People who are willing to give informed consent, accept being randomly assigned to one of the two treatments, and are able to attend follow-up appointments as required.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer has spread to nearby lymph nodes or to other parts of the body, based on standard staging tests.
  • People with more than one separate primary lung cancer at the same time that would need different treatment approaches, or where a single main tumour cannot be clearly identified for the study.
  • People who have previously had chest radiation treatment in an area that would overlap with the planned radiation treatment in this trial, or who have already had a local treatment to the same tumour being studied.
  • People with another active cancer that is likely to affect how results are measured — for example, a cancer requiring ongoing drug treatment or one that is expected to affect survival within 2 years — with the exception of certain low-risk, previously treated skin cancers or pre-cancerous conditions.
  • People who cannot safely have bronchoscopy (a procedure involving a camera into the airways) due to risks from sedation or anaesthesia, or people who have medical conditions that prevent them from being safely positioned for or receiving SBRT radiation treatment.
  • People whose tumour is considered unsafe or not technically possible to treat with either of the two methods, as judged by the relevant specialist teams.
  • Women who are pregnant or breastfeeding.
  • People who are unable or unwilling to follow the study procedures or attend required follow-up.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026

Contact this trial

Principal Investigator: Calvin Sze Hang Ng, CUHK

Phone: 85235052618

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 August 2026
Est. completion
30 November 2029

Where this trial is recruiting

Hong Kong

Primary endpoints

Local tumour control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov